Company intelligence / Profile preview

Impactiv

Ownership: Private
Development stage: Other

Overview

ImPact Biotech is developing padeliporfin VTP, a novel oncology platform for selective tumor ablation. The technology offers surgery-like efficacy for patients with localized solid tumors who are either ineligible for surgery or would experience significant morbidity from surgical intervention. The company is currently at a clinical development stage, though specific trial results or phases are not publicly detailed.

Therapeutic areas: Oncology
Modalities: Small moleculePhotodynamic therapy (Vascular Targeted Photodynamic therapy)
Industry: Biotech

Beyond the preview

Go deeper on Impactiv.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Impactiv.

Explore the full profile